Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the anal

SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Compan

Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with

Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Pote

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Pote

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDA

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon

US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus

US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, com

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stag

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breas

Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and b

Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and b

Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovati

Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer e

Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer e

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(1.11) per share which missed the an

SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company

Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer r

RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases

Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atoss

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a B

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.03) per share which beat the anal

SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Comp

Hyperfine (NASDAQ: HYPR - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary

Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.

Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarker

Shares of Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) have earned a consensus recommendati

Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) saw a large growth in short interest during th

SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Co

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q

  On Thursday, 241 companies hit new 52-week lows.

  Monday saw 825 companies set new 52-week lows.

  On Thursday, 1076 companies hit new 52-week lows.

  On Wednesday, 340 stocks hit new 52-week lows.

  On Wednesday, 215 companies set new 52-week lows.

  On Tuesday, 540 companies set new 52-week lows.

  On Friday, 1043 companies hit new 52-week lows.

  On Friday, 431 companies hit new 52-week lows.

Gainers